Noppens RR, Dar FI, Banik S. Comparison of the novel membrane-based carbon dioxide filter memsorb™ with a chemical granulate absorbent using a high-fidelity lung simulator: a prospective randomized in vitro trial.
Can J Anaesth 2023;
70:1643-1647. [PMID:
37697100 DOI:
10.1007/s12630-023-02563-7]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 02/16/2023] [Accepted: 02/16/2023] [Indexed: 09/13/2023] Open
Abstract
PURPOSE
Memsorb™ is a novel device for carbon dioxide (CO2) removal from anesthesia circuits via a semipermeable polymeric membrane. We evaluated the performance of the memsorb device for the removal of CO2 in an Aisys™ CS2 machine and compared it with a standard chemical granulate absorber (CGA) using a high-fidelity lung simulator.
METHODS
We used an in vitro lung simulator (DUCt) to control CO2 release by imitating alveolar gas exchange. The ventilator settings were identical for all measurements. The fresh gas flow (FGF) was randomized to either 0.5 L·min-1 or 2 L·min-1, completing three trials for each FGF for either memsorb or CGA. The EtCO2 and FICO2 levels were recorded for 30 min in each setting.
RESULTS
EtCO2 was comparable between the groups with 2 L·min-1 FGF over the observation period. FICO2 was significantly higher in the memsorb group during the trial (2 L·min-1; 3.9 mm Hg; 95% CI, 4.4 to 3.3; P < 0.001). EtCO2 with 0.5 L·min-1 FGF was higher with memsorb than with CGA over the observation period (3.7 mm Hg; 95% CI, 2.7 to 4.7; P = 0.004). With 0.5 L·min-1 FGF, FICO2 was significantly higher in the memsorb group compared with CGA over the whole observation period (6 mm Hg; 95% CI, 6.4 to 5.5; P < 0.001).
DISCUSSION
CO2 was successfully removed from the anesthesia circuit. FICO2 was significantly higher with memsorb throughout the observation period. Nevertheless, the clinical impact of these observations remains unclear. Further clinical trials are required to determine the utility of the novel device.
Collapse